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Background/Objective: Evidence from basic and clinical studies suggests that
unsaturated fatty acids (UFAs) might be relevant mediators of the development of
complications in acute pancreatitis (AP). Objective: The aim of this study was to analyze
outcomes in patients with AP from regions in Spain with different patterns of dietary
fat intake.
Materials and Methods: A retrospective analysis was performed with data from
1,655 patients with AP from a Spanish prospective cohort study and regional nutritional
data from a Spanish cross-sectional study. Nutritional data considered in the study
concern the total lipid consumption, detailing total saturated fatty acids, UFAs and
monounsaturated fatty acids (MUFAs) consumption derived from regional data and not
from the patient prospective cohort. Two multivariable analysis models were used: (1) a
model with the Charlson comorbidity index, sex, alcoholic etiology, and recurrent AP; (2)
a model that included these variables plus obesity.
Results: In multivariable analysis, patients from regions with high UFA intake had
a significantly increased frequency of local complications, persistent organ failure
(POF), mortality, and moderate-to-severe disease in the model without obesity and a
higher frequency of POF in the model with obesity. Patients from regions with high
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MUFA intake had significantly more local complications andmoderate-to-severe disease;
this significance remained for moderate-to-severe disease when obesity was added to
the model.
Conclusions: Differences in dietary fat patterns could be associated with different
outcomes in AP, and dietary fat patterns may be a pre-morbid factor that determines
the severity of AP. UFAs, and particulary MUFAs, may influence the pathogenesis of the
severity of AP.
Keywords: acute pancreatitis, diet, fat intake, obesity, unsaturated fatty acids
INTRODUCTION
Acute pancreatitis (AP) is a common health issue (1).
While most patients have a mild disease course, one-third
experience local and/or systemic complications that produce an
increase of morbidity (2). Furthermore, patients with systemic
complications have a higher mortality, which is as high as 50%
among patients with persistent (>48 h) organ failure (POF) (2).
The factors that determine the development of complications in
AP are currently poorly understood. Obesity, particularly visceral
adiposity, is associated with local complications, with systemic
complications, and with increased risk of death (3–5). In vitro
experiments using acinar cells of the pancreas have shown that
unsaturated fatty acids (UFAs) are associated with inflammation
and necrosis, while saturated fatty acids (SFAs) are not harmful.
These experiments suggest that UFAs produce necrosis of acinar
pancreatic cells and uncontrolled UFA release results in highUFA
levels in the bloodstream and is associated with kidney failure
and with cell damage in lung alveoli (6, 7). UFAs have been
detected in pancreatic necrosis collections (6–9). Furthermore,
oleic acid chlorohydrin, a halogenated product derived from
monounsaturated oleic acid, was recently described as a blood
marker and mediator of complications in a rat model of AP (10)
and in patients with AP (11). Thus, UFA-mediated toxicity seems
to be a key pathway in determining complications of AP (11, 12).
Preceding studies have suggested that diet affects body fatty acid
composition. In animal models, mice with diets with different
content in oleic acid and linoleic acid show these differences on
the composition of fatty acids of their tissues. Studies in humans
also show this association (13, 14). Consequently, it is possible
that the changes induced by dietary UFAs can modulate the
severity of AP. To our knowledge, there are no clinical studies
studying this relationship. This study aimed to compare clinical
course of disease of AP in regions of Spain that have different
dietary fat intake patterns.
MATERIALS AND METHODS
This was a retrospective analysis of data from a prospective
cohort study, the Atlantis Project, plus data from a cross-sectional
Abbreviations:AP, acute pancreatitis; APFC, acute peripancreatic fluid collection;
BMI, body mass index; CCI, Charlson comorbidity index; H, High consume; IQR,
interquartile range; IRB, Institutional Review Board; L, Low consume; MUFA,
monounsaturated fatty acid; OR, odds ratio; POF, persistent organ failure; PUFA,
polyunsaturated fatty acid; SFA, saturated fatty acid; UFA, unsaturated fatty acid.
study, the ANIBES (Anthropometric data, macronutrients
and micronutrients intake, practice of physical activity,
socioeconomic data, and lifestyles in Spain) study.
The Atlantis Project was endorsed by the Spanish Association
of Pancreatology (AESPANC) and by the Spanish Association of
Gastroenterology (AEG). It aimed to validate and compare the
determinants of AP severity and the severity classifications of AP
(2) as well as to ascertain the role of comorbidity in the course
of AP (4). Described in detail elsewhere (2), the Atlantis project
was a 23-center nationwide prospective study which analyzed
1,655 patients with AP recruited from June 2013 to February
2015. All centers were tertiary care hospitals with availability
of critical care. In Spain, there is a public healthcare system
and citizens have similar access with similar quality of care in
the different regions of the country. The project was carried
out following the rules of the Declaration of Helsinki of 1975.
The study required written informed consent and was approved
by the Institutional Review Boards (IRBs) of the participating
centers. This new analysis was also approved by the central IRB
of the Atlantis study, namely the Comité Ético de Investigación
con Medicamentos del Hospital General Universitario de Alicante
(PI2018-102). For the diagnosis of AP, two or more criteria had to
be fulfilled: (A) typical upper abdominal pain; (B) serum amylase
and/or lipase levels that were at least three times greater than the
upper limit of normal; and (C) imaging compatible with AP (15).
Patients with a diagnosis of chronic pancreatitis were excluded.
Patient outcomes were recorded during their hospital stay, and
the following data were retrieved from the study database for
this analysis: local complications (acute peripancreatic fluid
collections or pancreatic and/or peripancreatic necrosis), POF,
mortality (in-hospital mortality), and disease severity (moderate-
to-severe disease). These were defined according to the revised
Atlanta classification (15). Obesity was defined as body mass
index ≥30 kg/m2.
The aim of the ANIBES study was to update the food and
beverage intake, behavior, and anthropometric measurements
of the Spanish citizens, as well as to determine their energy
expenditure and physical exercise habits (sample: 2009 citizens)
(16). Diet was studied using a dietary diary (during 3 days)
recorded on a tablet device plus a 24-h dietary recall. The
participants were explained that the diet during those 4 days had
to be representative of their diet of the past years. The ANIBES
study divided Spain into nine regions: Barcelona, Canary
Islands, Central, Levant, Madrid, North-East, North-West,
North-Central, and South (16). Data regarding the consumption
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of lipids, SFAs, monounsaturated fatty acids (MUFAs), and
polyunsaturated fatty acids (PUFAs) were retrieved from the
original ANIBES database. According to ANIBES, the Spanish
mean daily caloric intake is 1,810 kcal/day, including 38.5% from
lipids (overall), 11.7% from SFAs, and 23.43% from UFAs (16.8%
fromMUFA and 6.63% fromPUFAs) (17). Patients in the Atlantis
Project from regions that had intake levels that were higher than
the national mean values were considered to be high consumers
regarding that specific type of fatty acid, while patients from
regions that had intake levels that were lower than the Spanish
mean values were classified as low consumers. For example, the
national mean intake of UFAs is 23.6% (mean percentages of total
caloric intake) and the mean intake of UFAs in North-Central
region of Spain is 24.2%. Therefore, patients in the Atlantis
Project from North-Central region were considered to be high
consumers of UFAs. The differences in consumption of PUFAs
in the different regions of Spain are minimal, so we have not
included this type of fatty acid in the analysis.
Statistics
Continuous data were analyzed for normality by the Shapiro-
Wilk test and were summed-up using means and standard
deviations or medians and interquartile ranges (IQRs) depending
on the variable distribution. Qualitative variables were expressed
as number (n) and percentage (%). The association of low
or high fat consumption according to region and outcome
was investigated using a chi-square test or Fisher’s exact test
if necessary and using binary logistic regression analysis for
multivariable analysis. Two multivariable analysis models were
used: (1) a model without obesity that included age, comorbidity
(according to the Charlson comorbidity index, cutoff ≥3) (18),
sex, alcoholic etiology, and recurrent AP (≥1 previous episode);
(2) a model with obesity that included all of these variables
plus obesity. The adjusted odds ratios (ORs) were calculated.
Statistical calculations were done using SPSS 21.0 (IBM, Armonk,
NY, USA).
RESULTS
Table 1 shows the detailed baseline characteristics and outcomes
of the 1,655 patients with AP. The patients had a median age
of 66 years; 54% were male, 24% were obese, 60% had gallstone
etiology, 27% had local complications, 7% had POF, and 4% died.
Regarding these baseline characteristics, there were no significant
differences between the different regions of Spain (p > 0.05).
Supplementary Table 1 shows the caloric profile of lipid intake
of the Spanish population as stratified by region according to
the ANIBES study. Supplementary Table 2 lists the number of
medical centers and patients of the Atlantis database in the
regions defined in the ANIBES study.
Univariate Analysis
Table 2 shows outcomes according to lipid intake (univariate
analysis). Moderate-to-severe disease was more frequently
present in patients from regions with a high overall lipid intake
[37 vs. 32.1%, p = 0.04], who also showed a non-significant
trend toward a higher frequency of local complications [28.4
TABLE 1 | Baseline characteristics and outcomes of patients with acute
pancreatitis.
Characteristics and outcomes Overall
N 1,655
Age, years; median (IQR) 66 (51–79)
Male sex, n (%) 891 (53.8%)
BMI, kg/m2
Median (IQR) 26.8 (24.3–29.7)
BMI < 25 509 (31.5%)
BMI 25–<30 (Pre-Obesity) 722 (44.7%)
BMI ≥ 30 (Obesity) 383 (23.7%)
CCI, points; median (IQR) 3 (1–5)
Liver disease, n (%) 120 (7.2%)
Etiology, n (%)
Gallstones 984 (59.5%)
Alcohol 251 (15.2%)
Idiopathic 235 (14.2%)
Other 185 (11.2%)
Recurrent AP, n (%) 422 (25.5%)
Local complications, n (%)
Any local complication 444 (26.8%)
APFC 163 (9.8%)
Peri(pancreatic) necrosis 281 (17%)
Persistent organ failure, n (%) 113 (6.8%)
Mortality, n (%) 70 (4.2%)
IQR, interquartile range (Q1–Q3); BMI, body mass index; CCI, Charlson comorbidity
index; AP, acute pancreatitis; APFC, acute peripancreatic fluid collection; Peri(pancreatic)
necrosis, pancreatic and/or peripancreatic necrosis.
vs. 24.6%, p = 0.08]. Patients from regions with high intake
of UFAs had significantly more local complications [28.6 vs.
20.5%, p = 0.002], POF [7.7 vs. 3.8%, p = 0.01], mortality
[4.8 vs. 2.2%, p = 0.03], and moderate-to-severe disease [36.7
vs. 29%, p = 0.007]. Being from a region with high MUFA
intake was significantly associated with more local complications
[29.6 vs. 23.9%, p = 0.009] and moderate-to-severe disease [38.1
vs. 31.7%, p = 0.007]. SFA intake had no effect on outcomes
(Table 2).
Multivariable Analysis
In multivariable analysis (Table 3), patients from regions with
high overall lipid intake had significantly more frequent
moderate-to-severe disease in the model without obesity [OR
= 1.26; 95% CI: 1.02–1.55; p = 0.034], but high overall lipid
intake was not significant after obesity was included in the
model [OR = 1.19; 95% CI: 0.96–1.48; p = 0.1]. Patients
with AP from regions with high UFA intake had significantly
higher rates of local complications [OR = 1.53; 95% CI: 1.15–
2.05; p = 0.004], POF [OR = 2.1; 95% CI: 1.18–3.74; p =
0.01], mortality [OR = 2.37; 95% CI: 1.12–5.03; p = 0.02], and
moderate-to-severe disease [OR = 1.42; 95% CI: 1.1–1.85; p
= 0.007] in the model without obesity compared to patients
from areas with low UFA intake; after entering the variable
obesity into the model, high UFA intake remained a risk factor
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TABLE 2 | Outcomes of acute pancreatitis according to regional lipid intake.
Lipid Intake Outcomes: n (%)
Local complications Persistent organ failure Mortality Moderate-to-severe AP
Lipids (overall) High 278 (28.4%) 71 (7.3%) 43 (4.4%) 362 (37%)
Low 166 (24.6%) 42 (6.2%) 27 (4%) 217 (32.1%)
P 0.08 0.4 0.7 0.04
SFAs High 327 (26.9%) 79 (6.5%) 47 (3.9%) 430 (35.4%)
Low 117 (26.7%) 34 (7.7%) 23 (5.2%) 149 (33.9%)
P 0.9 0.4 0.2 0.6
UFAs High 369 (28.6%) 99 (7.7%) 62 (4.8%) 473 (36.7%)
Low 75 (20.5%) 14 (3.8%) 8 (2.2%) 106 (29%)
P 0.002 0.01 0.03 0.007
MUFAs High 252 (29.6%) 65 (7.6%) 39 (4.6%) 324 (38.1%)
Low 192 (23.9%) 48 (6%) 31 (3.9%) 255 (31.7%)
P 0.009 0.2 0.5 0.007
Percentages are the proportions of the patients of the whole cohort (high or low consumers) that show each outcome of AP.
SFAs, saturated fatty acids; UFAs, unsaturated fatty acids; MUFAs, monounsaturated fatty acids; High, patients from a region of Spain with a proportion of caloric intake from all lipids
or from the indicated types of lipids that was greater than the Spanish national mean; Low, patients from a region of Spain with a proportion of caloric intake from all lipids or from the
indicated types of lipids that was lower than the Spanish national mean; AP, acute pancreatitis; P, P-value in the chi-square test (Fisher’s exact test was not required).
Bold value indicates P-value statistically significant.
TABLE 3 | Multivariate analysis of high overall lipid intake and lipid subtype intake and outcomes in acute pancreatitis.
Lipid Model Adjusted odds ratio
Local complications Persistent organ failure Mortality Moderate-to-severe AP
Lipids (overall) Without obesity 1.21 (0.96–1.53)
P = 0.1
1.21 (0.82–1.8)
P = 0.3
1.15 (0.7–1.88)
P = 0.6
1.26 (1.02–1.55)
P = 0.034
With obesity 1.11 (0.88–1.41)
P = 0.4
1.23 (0.81–1.87)
P = 0.3
1.11 (0.66–1.87)
P = 0.7
1.19 (0.96–1.48)
P = 0.1
SFAs Without obesity 0.98 (0.76–1.26)
P = 0.9
0.87 (0.57–1.32)
P = 0.5
0.76 (0.45–1.28)
P = 0.3
1.06 (0.84–1.3)
P = 0.63
With obesity 1.01 (0.78–1.3)
P = 0.9
0.87 (0.57–1.34)
P = 0.5
0.83 (0.48–1.42)
P = 0.49
1.11 (0.88–1.4)
P = 0.4
UFAs Without obesity 1.53 (1.15–2.05)
P = 0.004
2.1 (1.18–3.74)
P = 0.01
2.37 (1.12–5.03)
P = 0.02
1.42 (1.1–1.85)
P = 0.007
With obesity 1.34 (0.99–1.83)
P = 0.06
2.4 (1.24–4.71)
P = 0.01
2.09 (0.94–4.66)
P = 0.07
1.27 (0.96–1.67)
P = 0.09
MUFAs Without obesity 1.3 (1.03–1.62)
P = 0.025
1.36 (0.92–2)
P = 0.1
1.29 (0.79–2.09)
P = 0.3
1.33 (1.08–1.63)
P = 0.008
With obesity 1.2 (0.95–1.5)
P = 0.1
1.37 (0.91–2.06)
P = 0.1
1.24 (0.75–2.07)
P = 0.4
1.26 (1.02–1.56)
P = 0.035
In the binary logistic regression analysis, the data are reported as adjusted odds ratios (95% confidence intervals) and P-values (reference group: low intake of lipids). Model, the model
used for multivariable analysis; Without obesity, the model that included Charlson comorbidity index (cutoff ≥3), sex, alcoholic etiology, and recurrent AP; With obesity, the model
that included these same variables plus obesity (body mass index ≥ 30 kg/m2 ); SFAs, saturated fatty acids; UFAs, unsaturated fatty acids; MUFAs, monounsaturated fatty acids; AP,
acute pancreatitis.
Bold value indicates P-value statistically significant.
for POF [OR = 2.4; 95% CI: 1.24–4.71; p = 0.01], showing
a non-significant trend for the other outcomes. Patients from
regions with high MUFA intake had significantly increased
rates of local complications [OR = 1.3; 95% CI: 1.03–1.62;
p = 0.025] and moderate-to-severe disease [OR = 1.33; 95%
CI: 1.08–1.63; p = 0.008], and the significance remained for
moderate-to-severe disease after entering the variable obesity
into the model [OR = 1.26; 95% CI: 1.02–1.56; p = 0.035].
SFA intake was not associated with any effect on outcomes
(Table 3).
DISCUSSION
Obesity is an important factor in AP severity and is associated
with worse outcomes (3, 4, 19). The Atlantis prospective cohort
study confirmed that obesity is associated with a higher mortality
and with a higher incidence of POF (4), and fatty acids could
be relevant mediators in the physiopathogenesis of moderate-to-
severe AP in obese patients. There is robust evidence from basic
research that UFAs are more toxic than SFAs (6, 7, 9, 12, 20–22).
Analysis of postmortem tissue from obese patients has shown
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that UFAs are the predominant fatty acids in the pancreas,
whereas the proportion of SFAs is lower (23, 24). Furthermore,
UFAs are the most common (70–75%) non-esterified fatty acids
in necrotic pancreatic collections (6–9). The Singh group has
performed in vitro studies using pancreatic acinar cells and has
studied animalmodels of AP and reports that UFAs are associated
with increased inflammation and necrosis, while SFAs are not
harmful (6, 7, 21, 22). These experiments suggest that (A) UFAs
are the consequence of lipolysis of visceral fat by pancreatic
lipases; (B) local UFAs produce necrosis of acinar pancreatic cells;
and (C) uncontrolled UFA release results in high UFA levels in
the bloodstream and is associated with renal tubular apoptosis
(and subsequently with kidney failure) as well as with cell damage
in lung alveoli that is similar to that seen in acute respiratory
distress syndrome (6, 7, 9, 12, 22). UFAs seem to induce cell death
by inhibiting mitochondrial complexes I and V and by increasing
intracellular calcium release (6, 25). In addition, in severe AP a
vicious cycle of inflammation and increasing oxidative stress is
created. UFAs, but not SFAs, are sensitive to oxidative metabolic
conditions and can worse this deleterious cycle in AP (26). This
role of UFA-mediated lipotoxicity in worsening AP is consistent
with the worse outcomes found in hypertriglyceridemic AP and
in obese patients with AP (4, 27). On the other hand, studies show
that dietary fatty acid patterns may affect body fat composition.
Mice fed diets that have higher oleic acid and lower linoleic acid
show differences in adipose tissue and fat composition of the
pancreas (23). Studies in humans show that the proportion of
different fatty acids of adipose tissue and plasma reflects, at least
in part, different dietary intake patterns (28–30).
UFAs are more toxic than SFAs, and body fat composition is
affected by dietary fatty acid intake. Thus, we hypothesized that
regional fat intake patterns could be associated with different
outcomes of AP. We also wanted to investigate whether dietary
fat patterns had an independent effect on outcomes when we
controlled for the presence of obesity. Accordingly, we compared
outcomes in patients from regions of Spain with different fat
intake levels. To our knowledge, this is the first study of its
kind, there are no clinical studies studying this association in
Spain or in other countries. Our study found that patients with
AP from areas with a high UFA consumption had significantly
higher rates of local complications, POF, mortality and frequency
of moderate-to-severe AP in univariate analysis; this effect was
also observed in multivariable analysis (for all four variables
in the model not including obesity and for POF in the model
including obesity). Patients from regions with high SFA intake
did not have a worse prognosis. It is well-known that POF
is the main determinant of severity in AP as reflected by the
severe disease category of the revised Atlanta classification,
which is defined exclusively by the presence of POF (15). Severe
AP entails the greatest morbidity and mortality (2). Taken
together, our results suggest that high UFA intake could be
an important pre-morbid factor in determining the severity of
AP (31).
Concerning the different types of UFAs, oleic acid is the
more important MUFA, is the predominant fatty acid in human
pancreatic extracts (23, 32) and in human pancreatic necrotic
collections (6, 7). In vitro and laboratory animal studies suggest
that oleic acid is associated with local and systemic toxicity
(7, 10, 11, 33–35). In addition, in a study by Pironi et al.
in patients with parenteral nutrition, the administration of a
lipid emulsion based on MUFA produces a higher inflammatory
status than in patients using a fish-oil based lipid emulsion (36).
In the present study, residing in a region with high MUFA
intake was independently associated with local complications
and with moderate-to-severe AP in the model without obesity
and with moderate-to-severe AP in the model that included
obesity. In addition, two studies investigated halogenated fatty
acids, a type of specific lipids produced from the oxidation
of fatty acids by hypochlorous acid, in humans and in an
animal model of AP. The animal model showed that the
induction of AP produces an important release of free fatty
acids from adipose tissue and also in the release of the
chlorohydrins of oleic acid. Only the chlorohydrin of oleic acid
was present in plasma (10). In humans, we found that oleic
acid chlorohydrin was an excellent early marker of moderate-to-
severe disease (11).
This study has several strengths, including the use of
multicenter data and nationwide prospective data from patients
with AP and the robust design and development of the
ANIBES study. There are also some limitations: we used indirect
data regarding dietary fat intake (regional consumption of fat
according to the ANIBES study) instead of obtaining individual
dietary data from every patient. It is difficult to conduct a
prospective study that involves a similar sample of patients
with detailed individual dietary information, and the lack of
validated food questionnaires for the analysis of dietary fat
and the different sources that are used in different countries
make it difficult to perform an international study. Furthermore,
dietary patterns are difficult to address in acutely ill patients,
as this usually involves self-registry of food intake. Finally, a
diet questionnaire is time-consuming, decreasing the feasibility
of such a study due to the high number of patients required to
reproduce our findings. However, we encourage the development
of a multicenter prospective cohort study, which would provide
more insights into the influence of lipids on AP. Besides, more
nutritional data should be analyzed in further studies as PUFA,
including the omega-6/omega-3 ratio that can be crucial in
inflammatory processes. This is a limitation of the study although
future studies by our group will include the omega-6/omega-
3 ratio in order to have a more complete and global vision of
the process. On the other hand, the de novo lipogenesis index
(the synthesis of new fatty acids from non-lipid sources) will be
evaluated in further studies by our research team. This index has
a known correlation with metabolic disorders such obesity and
type 2 diabetes and with inflammatory processes like moderate-
to-severe AP. Finally, the influence of dietary fat patterns with
possible similar pathophysiology could be studied in other severe
diseases like a sepsis.
In conclusion, differences in regional dietary fat patterns
seem to be associated with different outcomes of AP. Dietary
fat patterns could represent a significant pre-morbid factor that
determines the severity of AP. Moreover, UFAs, and particularly
MUFAs, seem to be important mediators of the pathogenesis of
the severity of AP.
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